Maze Therapeutics (MAZE) Profit After Tax (2024 - 2026)
Maze Therapeutics recorded quarterly Profit After Tax of -$24.2 million in Q1 2026, up 29.97% quarter-over-quarter from -$34.6 million in Q4 2025, and up 26.16% year-over-year from -$19.2 million in Q1 2025.
Maze Therapeutics' Profit After Tax history runs 3 years deep, the most recent figure standing at -$24.2 million for Q1 2026.
- In Q1 2026, Profit After Tax rose 26.16% year-over-year to -$24.2 million; the TTM figure through Mar 2026 stood at -$122.5 million (down 335.93% YoY), while the FY2025 annual figure was -$131.1 million, down 351.04% from the prior year.
- Profit After Tax came in at -$24.2 million for Q1 2026 at Maze Therapeutics, up from -$34.6 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $139.1 million in Q2 2024 to a low of -$34.6 million in Q4 2025.
- A 3-year average of -$11.5 million and a median of -$30.1 million in 2025 frame the typical range for Profit After Tax.
- Across the five-year window, Profit After Tax sank 124.22% in 2025 and gained 26.16% in 2026, its largest moves.
- Maze Therapeutics' Profit After Tax stood at -$29.6 million in 2024, then decreased by 16.87% to -$34.6 million in 2025, then rose by 29.97% to -$24.2 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$24.2 million, -$34.6 million, and -$30.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Maze Therapeutics | 1.37 Bn | 1.37 Bn | 18.21 Mn | -24.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.21 Mn |
| Dec 31, 2025 | -34.57 Mn |
| Sep 30, 2025 | -30.09 Mn |
| Jun 30, 2025 | -33.68 Mn |
| Mar 31, 2025 | -32.79 Mn |
| Dec 31, 2024 | -29.58 Mn |
| Sep 30, 2024 | -24.75 Mn |
| Jun 30, 2024 | 139.06 Mn |
| Mar 31, 2024 | -32.49 Mn |